Small-molecule inhibition of MDM2-p53 interaction augments radiation response in human tumors
Published version of a preprint
The DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.
Abstract
MDM2–p53 interaction and downstream signaling affect cellular response to DNA damage. AMG 232 is a potent small molecule inhibitor that blocks the interaction of MDM2 and p53. We examined the capacity of AMG 232 to augment radiation response across a spectrum of human tumor cell lines and xenografts. AMG 232 effectively inhibited proliferation and enhanced radiosensitivity via inhibition of damage repair signaling. Combined AMG 232 and radiation treatment resulted in the accumulation of γH2AX-related DNA damage and induction of senescence with promotion of apoptotic and/or autophagic cell death. Several molecules involved in senescence, autophagy, and apoptosis were specifically modulated following the combined AMG 232/radiation treatment, including FoxM1, ULK-1, DRAM, and BAX. In vivo xenograft studies confirmed more potent antitumor and antiangiogenesis efficacy with combined AMG 232/radiation treatment than treatment with drug or radiation alone. Taken together, these data identify the capacity of AMG 232 to augment radiation response across a variety of tumor types harboring functional p53. Mol Cancer Ther; 14(9); 1994–2003. ©2015 AACR.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Other MDM2 inhibitors were shown to enhance sensitivity to radiation in human xenografts [38, 39].”
From Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2 -Amplified and TP53 Wild-type Glioblastomas (2016) · cites this paper as [38]
Citations
Cites
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878 · cited 1×
“Using p53-null HCT116 ( / ) and PC3 cells, Lau and colleagues found that treatment with Nutlin-3 at 10 to 40 mmol/L suppressed cell growth and increased apoptosis by inhibiting the interaction of MDM2 and p73, a p53 isoform (38).”
BackgroundDRAM, a p53-Induced Modulator of Autophagy, Is Critical for Apoptosis
Crighton, D., Wilkinson, S., O'Prey, J., Syed, N., Smith, P., Harrison, P. R., Gasco, M., Garrone, O., Crook, T., & Ryan, K. M. (2006) · Cell · doi:10.1016/j.cell.2006.05.034 · Cited by 1,380
The Double-Edged Sword of Autophagy Modulation in Cancer
White, E., & DiPaola, R. S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5023 · Cited by 1,138 · cited 1×
“13 AMG 232 in combination with radiation induces programmed cell death Although autophagy is often induced under nutrient limiting conditions as a mechanism for maintaining cell viability, progressive autophagy can be cytotoxic and substitute for apoptosis in the induction of cell death (23, 24).”
BackgroundCycling hypoxia and free radicals regulate angiogenesis and radiotherapy response
Dewhirst, M. W., Cao, Y., & Moeller, B. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2397 · Cited by 1,022
Therapy-induced senescence in cancer.
Ewald, J. A., Desotelle, J. A., Wilding, G., & Jarrard, D. F. (2010) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djq364 · Cited by 824 · cited 1×
“Therapy-induced senescence is now recognized for its contribution to the overall loss of tumor cell viability (28).”
BackgroundSenescing human cells and ageing mice accumulate DNA lesions with unrepairable double-strand breaks
Sedelnikova, O. A., Horikawa, I., Zimonjic, D. B., Popescu, N. C., Bonner, W. M., & Barrett, J. C. (2004) · Nature Cell Biology · doi:10.1038/ncb1095 · Cited by 790 · cited 2×
“AMG 232 in combination with radiation induces cellular senescence Because gH2AX is also associatedwith senescence by binding to dysfunctional telomeres at the end of double strands (18), we investigated the effect of AMG 232 and radiation on cell senescence by examining several senescencemarkers.”
BackgroundDrugging the p53 pathway: understanding the route to clinical efficacy
Khoo, K. H., Verma, C. S., & Lane, D. P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4236 · Cited by 719 · cited 2×
“The p53 tumor suppressor is a key modulator of tumorigenesis and a central target in cancer therapy (1).”
BackgroundJC-1: alternative excitation wavelengths facilitate mitochondrial membrane potential cytometry
Perelman, A., Wachtel, C., Cohen, M., Haupt, S., Shapiro, H., & Tzur, A. (2012) · Cell Death & Disease · doi:10.1038/cddis.2012.171 · Cited by 699 · cited 5×
“5B, a significant reduction of JC-1 uptake, as indicated a reduced red/green fluorescence ratio, was observed in the combined treatment when compared with single treatments alone, indicating disruption of mitochondrial membrane integrity.”
BackgroundMethodInfluentialThe ULK1 complex: Sensing nutrient signals for autophagy activation
Wong, P.-M., Puente, C., Ganley, I. G., & Jiang, X. (2013) · Autophagy · doi:10.4161/auto.23323 · Cited by 497
Zhao, Y., Aguilar, A., Bernard, D., & Wang, S. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501092z · Cited by 462 · cited 1×
“Recent studies have demonstrated the antitumor capacity of small molecule MDM2 inhibitors both in vitro and in vivo, and several of these compounds have advanced to clinical trials (1, 6).”
Background
Cited by
MDM2 inhibition: an important step forward in cancer therapy
Konopleva, M., Martinelli, G., Daver, N., Papayannidis, C., Wei, A., Higgins, B., Ott, M., Mascarenhas, J., & Andreeff, M. (2020) · Leukemia · doi:10.1038/s41375-020-0949-z · Cited by 376
Tisato, V., Voltan, R., Gonelli, A., Secchiero, P., & Zauli, G. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0500-5 · Cited by 256
“In terms of potential molecular biomarkers, treatment with RG7112 led to increased expression of several P53 target genes including BAX, PUMA, FDXR, MDM2, ZMAT3, FAS, TNFRSF10B, CDKN1A, and TP53NP1 in circulating P53 wild-type leukemic cells following different kinetics of activation [96].”
BackgroundMDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future
Wang, W., Albadari, N. G., Du, Y., Fowler, J. F., Sang, H. T., Xian, W., McKeon, F., Li, W., Zhou, J., & Zhang, R. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.123.001026 · Cited by 172
“For example, inhibition of MDM2 with AMG232 enhanced the sensitivity of multiple cancer cell lines to radiation (Werner et al., 2015).”
BackgroundVerreault, M., Schmitt, C., Goldwirt, L., Pelton, K., Haidar, S., Levasseur, C., Guehennec, J., Knoff, D., Labussière, M., Marie, Y., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1015 · Cited by 114
“Other MDM2 inhibitors were shown to enhance sensitivity to radiation in human xenografts (37, 38).”
BackgroundMedicinal Chemistry Strategies to Disrupt the p53–MDM2/MDMX Interaction
Lemos, A., Leão, M., Soares, J., Palmeira, A., Pinto, M., Saraiva, L., & Sousa, M. E. (2016) · Medicinal Research Reviews · doi:10.1002/med.21393 · Cited by 81
Metadata
- Authors
- Werner, L. R., Huang, S., Francis, D. M., Armstrong, E. A., Ma, F., Li, C., Iyer, G., Canon, J., & Harari, P. M.
- Affiliations
- University of Wisconsin–Madison (US)
- Amgen (United States) (US)
- Corresponding author
- Harari, Paul M.
- Venue
- Molecular Cancer Therapeutics
- Published
- 2015-09-01
- Volume
- 14
- Issue
- 9
- Pages
- 1994-2003
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2130766483
- Cited by
- 45
- References
- 44
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 2 · 2023: 5 · 2022: 6 · 2021: 6 · 2020: 3 · 2019: 2 · 2018: 3 · 2017: 4 · 2016: 6 · 2015: 2
- FWCI
- 2.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Molecular Cancer Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Effects of Radiation Exposure
- Keywords
- p53-MDM2 interaction, small molecule inhibitors, radiosensitization, radiation response, DNA repair, γH2AX, cellular senescence, apoptosis, autophagy, FOXM1, DRAM, Bax, angiogenesis inhibition, tumor xenografts
- MeSH terms
- Acetates, Animals, Antineoplastic Agents, Autophagy, Cell Survival, Disease Models, Animal, Humans, Neoplasms, Piperidones, Protein Binding, Radiation Tolerance, Radiation, Ionizing, Signal Transduction, Tumor Suppressor Protein p53, Cellular Senescence, Apoptosis, Xenograft Model Antitumor Assays, Cell Line, Tumor, Cell Proliferation, Mice, Proto-Oncogene Proteins c-mdm2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Small-molecule inhibition of MDM2-p53 interaction augments radiation response in human tumors. https://app.cochat.ai/papers/10.1158/1535-7163.mct-14-1056-t
- The paper
- Werner, L. R., Huang, S., Francis, D. M., Armstrong, E. A., Ma, F., Li, C., Iyer, G., Canon, J., & Harari, P. M. (2015). Small-molecule inhibition of MDM2-p53 interaction augments radiation response in human tumors. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-14-1056-t
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.